BioPharma Resources

Drug Trial Radar · NCT07494305

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Jan 23, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
LB Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.

Conditions

  • Bipolar I Disorder

Interventions

  • LB-102Drug

    N-methyl amisulpride

  • PlaceboOther

    Inactive substance that looks identical to the active treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery Åsberg Depression Rating -10 core symptom scale (MADRS-10)Time frame: Baseline to Day 42

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Pillar Clinical Research

    Bentonville, Arkansas · Recruiting

  • Pillar Clinical Research

    Little Rock, Arkansas · Recruiting

  • CenExel

    Bellflower, California · Recruiting

  • ProScience Research Group

    Culver City, California · Recruiting

  • CenExel

    Garden Grove, California · Recruiting

  • Synergy San Diego

    Lemon Grove, California · Recruiting

  • NRC Research Institute

    Los Angeles, California · Recruiting

  • NRC Research Institute

    Orange, California · Recruiting

  • CenExel

    Riverside, California · Recruiting

  • CenExel

    Torrance, California · Recruiting

  • St. Jude Clinical Research

    Doral, Florida · Recruiting

  • Cenexel Hollywood Florida

    Hollywood, Florida · Recruiting

  • Innovative Clinical Research

    Miami Lakes, Florida · Recruiting

  • Health Synergy Clinical Research

    West Palm Beach, Florida · Recruiting

  • Trialmed

    Atlanta, Georgia · Recruiting

  • Cenexel Decatur GA

    Decatur, Georgia · Recruiting

  • Pillar Clinical Research

    Chicago, Illinois · Recruiting

  • NSRT

    Detroit, Michigan · Recruiting

  • Arch Clinical Trials

    St Louis, Missouri · Recruiting

  • Redbird Research

    Las Vegas, Nevada · Recruiting

  • Manhattan Behavioral Medicine

    New York, New York · Recruiting

  • Neuro-Behavioral Clinical Research

    Canton, Ohio · Recruiting

  • Adams Clinical

    Philadelphia, Pennsylvania · Recruiting

  • Adams Clinical

    DeSoto, Texas · Recruiting

  • Pillar Clinical Research

    Richardson, Texas · Recruiting

  • Northwest Clinical Research Center

    Bellevue, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.